Zura Bio Limited (ZURA) - News Archive

Zura Bio Reports Third Quarter 2025 Financial Results and Recent Corporate Updates In a recent announcement, Zura Bio Limited (NASDAQ: ZURA) reported its financial results for the third quarter of 2025, revealing critic...

In the fast-paced world of biotech, Zura Bio Limited (Nasdaq: ZURA), a clinical-stage company specializing in multi-asset immunology and the development of novel dual-pathway antibodies, has made noteworthy strides in i...

In a pivotal move for the clinical-stage immunology field, Zura Bio Limited (Nasdaq: ZURA) has announced the submission of a protocol for a Phase 2 study of tibulizumab to the U.S. Food and Drug Administration (FDA). Ti...

Zura Bio s Strategic Advancements in Immunology: A Comprehensive Overview of Q2 2024 Financial Results and Key Clinical Progressions HENDERSON, Nev. Zura Bio Limited (Nasdaq: ZURA), a pioneering clinical-stage immunolog...

HENDERSON, Nev. Zura Bio Limited (Nasdaq: ZURA), a leading clinical-stage immunology company specializing in the development of innovative dual-pathway antibodies for the treatment of autoimmune and inflammatory disease...

In a recent announcement, Zura Bio Limited, a clinical-stage immunology company focused on developing innovative dual-pathway antibodies for autoimmune and inflammatory diseases, disclosed the expiration and outcomes of...

HENDERSON, Nev. Zura Bio Limited (Nasdaq: ZURA), an emergent force in the immunology field, has taken a significant stride forward with the release of encouraging data from its Phase 1 study of tibulizumab (ZB-106) at t...